The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod The post Dewpoint Therapeutics secures funding for DPTX3186 development appeared first on Pharmaceutical Business review.